Viatris Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Scott Andrew Smith
- Full Time Employees
- 30,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Robert J. Coury Global Center Canonsburg PA United States of America 15317
- IPO Date
- Mar 17, 1980
- CIK
- 0001792044
- Website
- viatris.com
- Similar Companies
- Business
- Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that develops, manufactures and markets a broad portfolio of branded and generic pharmaceuticals, biosimilars and complex generics; key brands include Lipitor, Norvasc, Viagra, Lyrica, Xanax, Creon, Celebrex, Effexor, Zoloft and EpiPen auto-injectors; generics and branded generics span therapeutic areas such as cardiovascular, central nervous system, infectious diseases, oncology, immunology, women's health, diabetes, gastroenterology, respiratory, allergy and dermatology; additional offerings encompass complex generics like Breyna (generic Symbicort), recent launches including Iron Sucrose Injection USP for iron deficiency anemia and Ryzumvi (phentolamine ophthalmic solution) for mydriasis; the company operates in developed markets, emerging markets, JANZ (Japan, Australia, New Zealand) and Greater China, supplying medicines to approximately 1 billion patients annually through global manufacturing and supply chain infrastructure. Headquartered in Canonsburg, Pennsylvania, Viatris was formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. Recent developments include the completion of the acquisition of Aculys Pharma Inc. in 2025, securing exclusive rights to pitolisant for narcolepsy and obstructive sleep apnea in Japan and Spydia Nasal Spray for status epilepticus in Japan and certain Asia-Pacific markets; submission of a New Drug Application to the U.S. FDA for a low-dose estrogen weekly patch, with anticipated approval by mid-2026; prior divestitures in 2023-2024 of its OTC business to Cooper Consumer Health, women's healthcare business and India API operations for approximately $3.6 billion; an ongoing enterprise-wide strategic review initiated in February 2025 to identify operating efficiencies in commercial, R&D, supply chain and corporate functions; and a December 2024 U.S. FDA warning letter and import alert on its Indore, India facility impacting 11 products, prompting corrective actions.
Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Is Viatris Inc (VTRS) Worth the Investment After Q2 Earnings? EPS at $0.69, Revenue of $3,756.8 Million with GF Score of 58/100
Viatris Reports Second-Quarter 2026 Financial Results
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
Viatris Announces Quarterly Dividend
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
VTRS or DHR: Which Is the Better Value Stock Right Now?
Should Value Investors Buy Viatris (VTRS) Stock?
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Viatris (VTRS) is a Great Momentum Stock: Should You Buy?